IP Library › Granted Patent US 12691094
Granted Patent B2
US 12691094 · App. 18/264,421 · Granted Jul 28, 2026

Use of Crassifolin A in preparation of drug for promoting mitophagy and treating neurodegenerative diseases

Inventors: Yubo Zhang (Guangzhou, CN); Fei Xiao (Guangzhou, CN); Guocai Wang (Guangzhou, CN); Evandro Fei Fang (Shanghai, CN); Junping Pan (Guangzhou, CN)
Assignee: JINAN UNIVERSITY
A61K31/365A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12691094
App. No.
18/264,421
Granted
Jul 28, 2026
Kind
B2
Abstract

Disclosed in the present invention is the use of Crassifolin A in promoting mitophagy and treating neurodegenerative diseases. According to the present invention, experiments show that the diterpene compound Crassifolin A can significantly increase mitophagy levels, promote the removal of damaged mitochondria, maintain homeostasis in cells, and has potential effects of treating neurodegenerative diseases and other related diseases; moreover, Crassifolin A is a small-molecule compound that can easily penetrate through the blood-brain barrier to reach the brain so as to play a role, can be extracted from a Thickleaf croton root medicinal material, has the advantages of abundant medicinal sources, easy availability, low drug toxicity and few side effects, and has a good application prospect in the treatment of neurodegenerative diseases.

Claims (7)

1 . A method for promoting cellular mitophagy in vitro, comprising providing an effective amount of Crassifolin A to cultured human cells, wherein the Crassifolin A has the following chemical structural formula as shown in Formula (I):

2 . The method according to claim 1 , wherein the effective concentration of the provided Crassifolin A is 5-15 μmol/L.

3 . The method according to claim 2 , wherein the effective concentration of the provided Crassifolin A is 10 μmol/L.

4 . A method for treatment of a neurodegenerative disease, comprising administering to a subject an effective amount of Crassifolin A, wherein the Crassifolin A has the following chemical structural formula as shown in Formula (I):

thereby treating the neurodegenerative disease.

5 . The method according to claim 4 , wherein the the Crassifolin A promotes mitophagy and inhibits expression of phosphorylated Tau, thereby treating the neurodegenerative disease.

6 . The method according to claim 4 , wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, a spinal cerebellar ataxia, Pick's disease, cerebral ischemia, brain injury, and epilepsy.